China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Britain Courts Anthropic Amid US Defense Department Dispute 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
MENLO PARK, Calif., Oct. 13, 2016 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced that Dr. Samuel Barone, MD, Senior Vice President, Clinical Development will provide a brief corporate overview and data presentation today at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting in Chicago, IL.
The presentation is now available on the Company’s website at www.adverumbio.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet AMD, A1AT deficiency, and hereditary angioedema, among other diseases. We are leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit www.adverumbio.com
Contact for Adverum: Tricia Truehart Vice President The Trout Group LLC 646-378-2953 [email protected]
